The effect of linoleic, arachidonic and eicosapentaenoic acid supplementation on prostacyclin production in rats.
We examined the effect of dietary supplementation of linoleic acid (LA), arachidonic acid (AA) or eicosapentaenoic acid (EPA) to rats fed a diet low in linoleic acid on in vitro and in vivo production of prostacyclin. Male Sprague Dawley rats were fed a high-fat diet (50% energy as fat, 1.5% linoleic acid) for two weeks. Three of the groups were then supplemented orally with either 90 mg/d of LA, AA or EPA, all as the ethyl esters, for a further two weeks while remaining on the high-fat diet. Forty-eight hour urine samples were collected at the end of the second and fourth weeks. In vivo prostacyclin production was determined by a stable isotope dilution, gas chromatography/mass spectrometry assay for the major urinary metabolite of prostacyclins (2,3-dinor-6-keto-PGF1 alpha or PGI2-M and delta 17-2,3-dinor-6-keto-PGF1 alpha or PGI3-M). In vitro prostacyclin production was determined by radioimmunoassay of the stable metabolite (6-keto-PGF 1 alpha) following incubation of arterial tissue. Oral supplementation with AA resulted in a rise in plasma and aorta 20:4n-6, and increased in vitro prostacyclin and urinary PGI2-M production. EPA supplementation resulted in a rise in plasma and aorta 20:5n-3 and 22:5n-3, and a decline in plasma 20:4n-6, but not in the aorta. In the EPA-supplemented group, the in vitro prostacyclin and the urinary PGI3-M increased, but urinary PGI2-M decreased. The increase in in vitro prostacyclin production in the EPA-supplemented rats was unexpected and without obvious explanation.(ABSTRACT TRUNCATED AT 250 WORDS)
Mann
N J
NJ
School of Nutrition and Public Health, Deakin University, Geelong, Victoria, Australia.
Warrick
G E
GE
O'Dea
K
K
Knapp
H R
HR
Sinclair
A J
AJ
D000818:Animals; D001013:Aorta, Thoracic / Q000737:chemistry; D016718:Arachidonic Acid / Q000494:pharmacology*; D004041:Dietary Fats / Q000494:pharmacology; D015118:Eicosapentaenoic Acid / Q000494:pharmacology*; D011464:Epoprostenol / Q000096:biosynthesis* / Q000652:urine; D005227:Fatty Acids / Q000032:analysis; D008401:Gas Chromatography-Mass Spectrometry; D066298:In Vitro Techniques; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000494:pharmacology*; D008297:Male; D010743:Phospholipids / Q000097:blood / Q000737:chemistry; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley
D004041:Dietary Fats; D005227:Fatty Acids; D008041:Linoleic Acids; D010743:Phospholipids; D016718:Arachidonic Acid; D019787:Linoleic Acid; D015118:Eicosapentaenoic Acid; D011464:Epoprostenol